Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab + ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The nivolumab and ipilimumab combination indication for unresectable or metastatic melanoma expanded to patients aged 12 or older.
LAMPGEN ANALYSIS
Why it matters
The paired supplements extended combined checkpoint blockade into adolescent melanoma.
What research teams should watch
Verify pediatric age and dosing and plan immune-related toxicity surveillance for the combination.
PRIMARY RECORDS